United Therapeutics (UTHR) CEO Rothblatt Sells 9,500 Shares

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, sold 9,500 shares of the company on June 22, 2026. This transaction was not part of a pre-arranged plan. The sale comes as the stock traded near $544.4 on the NasdaqGS on Wednesday.

Insider Buying and Selling at United Therapeutics Corporation

Martine Rothblatt sold 9,500 shares at an average price of $537.74 on June 22, 2026. This sale was not conducted under a Rule 10b5-1 plan. On the same day, James Edgemond, the CFO and Treasurer, also sold 8,750 shares at an unspecified price.

Other Institutional Activity in United Therapeutics

BlackRock, Inc. increased its holdings by 228,883 shares, ending with 5,399,649 shares valued at about $3.20 billion, a 4.4% increase. Avoro Capital Advisors LLC added 23,940 shares, bringing its total to 2,630,000 shares worth approximately $1.56 billion, marking a 0.9% increase. Wellington Management Group LLP, however, reduced its holdings by 177,245 shares, holding 2,264,247 shares valued at $1.34 billion, a 7.3% decrease. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions with 2,003,742 and 1,957,539 shares, valued at $1.19 billion and $1.16 billion, respectively.

United Therapeutics Corporation Stock Up 1.0%

Shares of United Therapeutics Corporation (NasdaqGS:UTHR) traded near $544.4 on Wednesday. The company has a market cap of $22.85 billion and a P/E ratio of 19.91. Its beta is 0.573, indicating lower volatility compared to the market. The stock has seen a 52-week low of $272.12 and a high of $609.35. The 50-day moving average is $565.40, and the 200-day moving average is $497.47. United Therapeutics has a strong current ratio of 4.794 and a quick ratio of 4.116.

Recent Earnings

United Therapeutics reported revenue of approximately $3.17 billion, showing a slight decline in growth at -1.6%. The company achieved an EPS of $27.04, with a net margin of 40.62% and a return on equity of 20.26%. The next earnings report is scheduled for July 29, 2026.

Analysts Set New Price Targets

On May 7, 2026, RBC Capital maintained its 'buy' rating on United Therapeutics with a price target of $701. Wells Fargo also upgraded its rating to 'buy', setting a target of $738. Meanwhile, Morgan Stanley maintained a 'hold' rating with a target of $519 on April 10, 2026. According to the consensus from 13 analysts, the stock has a 'buy' recommendation with a mean target price of $665.23.

About United Therapeutics

United Therapeutics Corporation, based in Silver Spring, Maryland, develops and sells products for chronic and life-threatening diseases like pulmonary arterial hypertension. The company offers various treatments, including Tyvaso DPI and Remodulin, and is involved in developing innovative therapies such as xenografts for organ transplantation. Founded in 1996, United Therapeutics is led by Dr. Martine A. Rothblatt and employs around 1,400 people.

Bottom Line

The recent insider selling by CEO Martine Rothblatt comes amid mixed institutional activity and updated analyst ratings for United Therapeutics. Investors watching these developments should remember that insider transactions and 13F filings reflect past actions and may not indicate current or future positions.